Clinical Trials
4
Active:0
Completed:2
Trial Phases
1 Phases
Phase 4:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 4
3 (100.0%)Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
Phase 4
- Conditions
- Post-Viral Fatigue SyndromePost-Viral Disorder (Disorder)Covid19
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- IMMUNOe Research Centers
- Target Recruit Count
- 40
- Registration Number
- NCT04705831
- Locations
- 🇺🇸
IMMUNOe Research Centers, Centennial, Colorado, United States
A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
Phase 4
Completed
- Conditions
- CVI - Common Variable Immunodeficiency
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- IMMUNOe Research Centers
- Target Recruit Count
- 20
- Registration Number
- NCT03576469
- Locations
- 🇺🇸
IMMUNOe Research Centers, Centennial, Colorado, United States
A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Phase 4
- Conditions
- Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal InfectionsPediatric Acute-Onset Neuropsychiatric Syndrome
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- IMMUNOe Research Centers
- Target Recruit Count
- 21
- Registration Number
- NCT03348618
- Locations
- 🇺🇸
IMMUNOe Research Centers, Centennial, Colorado, United States
🇺🇸Midwest Pediatrics, Papillion, Nebraska, United States
🇺🇸Allergy, Asthma & Immunology Relief Research Institute, Charlotte, North Carolina, United States
The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations
Completed
- Conditions
- Primary Immunodeficiency
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- IMMUNOe Research Centers
- Target Recruit Count
- 15
- Registration Number
- NCT03339778
News
No news found